Clinical Trial Update: A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of pimavanserin for Parkinson's disease psychosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: Tasly Pharmaceutical Group Co., Ltd | Conditions: Parkinson's Disease Psychosis | Phase 3 | Status: COMPLETED